Important note: Information in this article was accurate in 2002. The state of the art may have changed since the publication date.
|
|
USA Today (12.31.02) - Tuesday, December 31, 2002
Rita Rubin
"The 134 cases of suspected post transfusion hepatitis... emphasize the dangerously cavalier attitude of previous ARC statements of assurance about the safety of the blood supply," Public Citizen's Health Research Group Director Sidney Wolfe said Monday in a letter to Sen. Edward Kennedy (D-Mass.), the ranking minority member of the Senate Health, Education, Labor and Pension Committee.
"The FDA and the Red Cross agree that the nation's blood supply today is safer than it has ever been in our nation's history," Red Cross official Ramesh Thandani said in a Dec. 20 statement. "However, the Red Cross understands more work needs to be done to further strengthen our processes and procedures, and we are fully committed to working collaboratively with the FDA to enhance our systems."
The suspected post-transfusion hepatitis cases occurred between Jan. 1, 2000 and June 30, 2002. The FDA said that by not investigating these cases, the Red Cross violated a 1993 consent degree ordering it to clean up its blood division.
Unless a member region requests otherwise, the Red Cross does not investigate hepatitis cases when more than 10 blood donors are involved. In January 2001, the Northern Ohio Region asked the Red Cross to allow it to investigate the case of a patient who tested positive for hepatitis after receiving blood from 36 donors. The Ohio region's investigation revealed that one of the donors had been involved in a previous case of suspected post-transfusion hepatitis.
Even when fewer donors are involved and an investigation is conducted, the Red Cross does not dig deeply enough, the FDA report said. In a statement after the inspection report was released, FDA Commissioner Mark McClellan said, "I am troubled by the apparent lapses in blood safety practices."
021231
AD022517
Copyright © 2002 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.
Always watch for outdated information. This article first appeared in 2002. This material is designed to support, not replace, the relationship that exists between you and your doctor.AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2002. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.
.